Research

For over 30 years, the research department at OSF HealthCare Cardiovascular Institute has participated in research trials at our Peoria and Rockford offices. The research trials study cardiovascular medications and/or devices in general cardiology, interventional cardiology, electrophysiology, heart failure, vascular care and cardiothoracic care.

Research

For over 30 years, the research department at OSF HealthCare Cardiovascular Institute has participated in research trials at our Peoria and Rockford offices. The research trials study cardiovascular medications and/or devices in general cardiology, interventional cardiology, electrophysiology, heart failure, vascular care and cardiothoracic care.

Many of our research trials are sponsored by international drug and device companies, while other trials are initiated by OSF HealthCare Cardiovascular Institute providers.

All of our studies are approved by the Peoria Institutional Review Board (IRB) at the University of Illinois College of Medicine. The IRB is an ethical review board who protects human rights for those participating in research trials.

OSF HealthCare Cardiovascular Institute is proud to contribute to medical science through our trials and be a part of many state-of-the-art treatments being approved by the Food and Drug Administration (FDA). Through our research, we are able to deliver the most appropriate and advanced treatment options to our patients.

Medication Trials

  • A-DUE

  • A-DUE: Efficacy and safety of Macitentan and Tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with Macitentan and Tadalafil fixed dose combination therapy.

  • AEGIS II

  • AEGIS II: Efficacy and safety of CSL112 in subjects with Acute Coronary Syndrome.

  • PARAGLIDE HF

  • PARAGLIDE HF: Effects of Entresto vs Valsartan on changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with acute decompensated heart failure who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge.

  • SOS-AMI

  • SOS-AMI: Selatogrel Outcome Study in suspected Acute Myocardial Infarction.

  • VICTOR

  • VICTOR: Evaluate the efficacy and safety of the sGC Stimulator Vericiguat in Adults with chronic Heart Failure with reduced ejection fraction.

Device Trials

  • PRESERVE II

  • PRESERVE II: Clinical study to evaluate the safety and effectiveness of Zenith Branch Endovascular Graft-Iliac Bifurcation.

  • PROACTIVE HF

  • PROACTIVE HF: Safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III HF Patients.